drugset / Trial / NCT05830045
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
Timeline
- Start
- 2023-05-19
- Primary completion
- 2025-04-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLP2117 | Unknown | — | — |